^
Association details:
| Biomarker: | MGMT deletion |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | temozolomide (DNA synthesis inhibitor) + capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
06-methylguanine DNA methyltransferase deficiency and outcomes with CAPTEM in patients with pancreatic neuroendocrine tumours
Published date:
06/27/2023
Excerpt:
We performed an unicentric and retrospective analysis in patients (p) with advanced pNET undergoing treatment with CAPTEM....At the time of analysis, 41.6% of patients with Ki-67(3% and MGMT deficiency we observed a marked trend towards better PFS (88m [95%CI;19.5-156.4] vs 11.1m [95%CI;0.0-32.2]; p=0.02). Median OS was strongly lower in intact MGMT (35.8m [95%CI;0.1-71.4] vs 141.9m [95%CI; 0.0302.7]; p=0.03)....Our findings suggest that MGMT status tested by IHQ could be used as a predictive biomarker...
DOI:
https://doi.org/10.1016/j.annonc.2023.04.271
